Predicting the severity of mood and neuropsychiatric symptoms from digital biomarkers using wearable physiological data and deep learning.

Journal: Computers in biology and medicine
PMID:

Abstract

Neuropsychiatric symptoms (NPS) and mood disorders are common in individuals with mild cognitive impairment (MCI) and increase the risk of progression to dementia. Wearable devices collecting physiological and behavioral data can help in remote, passive, and continuous monitoring of moods and NPS, overcoming limitations and inconveniences of current assessment methods. In this longitudinal study, we examined the predictive ability of digital biomarkers based on sensor data from a wrist-worn wearable to determine the severity of NPS and mood disorders on a daily basis in older adults with predominant MCI. In addition to conventional physiological biomarkers, such as heart rate variability and skin conductance levels, we leveraged deep-learning features derived from physiological data using a self-supervised convolutional autoencoder. Models combining common digital biomarkers and deep features predicted depression severity scores with a correlation of r = 0.73 on average, total severity of mood disorder symptoms with r = 0.67, and mild behavioral impairment scores with r = 0.69 in the study population. Our findings demonstrated the potential of physiological biomarkers collected from wearables and deep learning methods to be used for the continuous and unobtrusive assessments of mental health symptoms in older adults, including those with MCI. TRIAL REGISTRATION: This trial was registered with ClinicalTrials.gov (NCT05059353) on September 28, 2021, titled "Effectiveness and Safety of a Digitally Based Multidomain Intervention for Mild Cognitive Impairment".

Authors

  • Yuri G Rykov
    Neuroglee Therapeutics, 2 Venture Dr, #08-18, Singapore, 608526.
  • Kok Pin Ng
    Department of Neurology, National Neuroscience Institute, 11 Jln Tan Tock Seng, 308433, Singapore; Duke-NUS Medical School, 8 College Rd, 169857, Singapore.
  • Michael D Patterson
    Neuroglee Therapeutics, 2 Venture Dr, #08-18, Singapore, 608526.
  • Bikram A Gangwar
    Neuroglee Therapeutics, 2 Venture Dr, #08-18, Singapore, 608526. Electronic address: bikram.gangwar@neuroglee.com.
  • Nagaendran Kandiah
    Dementia Research Centre, Lee Kong Chian School of Medicine, Nanyang Technological University, 11 Mandalay Road, Level 18 308232, Singapore.